NYSE - Delayed Quote USD

Eli Lilly and Company (LLY)

745.95

-4.82

(-0.64%)

At close: April 18 at 4:00 PM EDT

745.00

-0.95

(-0.13%)

After hours: April 18 at 7:59 PM EDT

13 Best Low Volatility Stocks to Buy According to Hedge Funds

In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds. The S&P 500 had a remarkable year in 2023 and the first quarter […]

Insider Monkey 6 hours ago

^GSPC

^VIX

TSM
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Investor's Business Daily 7 hours ago

RMD

LLY
-0.64%
NVO
-1.43%
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025

The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says that? The companies that make those drugs predict. The weight loss drug frenzy took off when the FDA approved Novo Nordisk A/S’s (NYSE:NVO) Wegvoy (semaglutide) in 2021. Eli Lilly And Co’s (NYSE:LLY) Zepbound (tirzepatide) appears to spur the momentum after receiving FDA approval in November 2023. According to the FDA, limited supplies of Eli Lilly’s d

Benzinga 8 hours ago

LLY
-0.64%
India's Biocon developing its own version of Wegovy, clinical trial likely next year

Indian drugmaker Biocon , looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.

Reuters 10 hours ago

BIOCON.NS

MITTAL.NS

NVO
-1.43%
Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?

Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?

Investor's Business Daily 11 hours ago

LLY
-0.64%
NVO
-1.43%
BIIB
-0.85%
Company News for Apr 18, 2024

Companies In The Article are: LLY,ADSK,MBLY,USB

Zacks 14 hours ago

LLY
-0.64%
MBLY

ADSK
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.

Zacks 14 hours ago

LLY
-0.64%
NVO
-1.43%
14 Best Large Cap Dividend Growth Stocks To Buy Now

In this article, we discuss 14 best large-cap dividend growth stocks to buy now. You can skip our detailed analysis of large-cap dividend stocks and their historical performance, and go directly to read 5 Best Large Cap Dividend Growth Stocks To Buy Now. Large-cap stocks have remained ideal for investors as they typically form the […]

Insider Monkey 15 hours ago

UPS

AXP

TGT
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years

These stocks have taken different paths to where they are today, but both have been exceptional investments.

Motley Fool 18 hours ago

TSLA

LLY
-0.64%
The Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo

Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo are included in this Analyst Blog.

Zacks 19 hours ago

CAT

LLY
-0.64%
Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company acquired a portfolio of medicines it aims to test in combination.

BioPharma Dive 20 hours ago

LLY
-0.64%
NVO
-1.43%
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank

The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.

Motley Fool yesterday

LLY
-0.64%
RMD

AHCO
Top Research Reports for Eli Lilly, Linde & Caterpillar

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Linde plc (LIN) and Caterpillar Inc. (CAT).

Zacks yesterday

CAT

LLY
-0.64%
WFC
Stocks Fall After Fed Data; Nvidia Tests Key Level While Tesla's Musk Faces Shareholder Vote

Stocks were mixed ahead of Fed data Wednesday. ASML sold off after earnings. Nvidia remained in a base.

Investor's Business Daily yesterday

TSLA

LLY
-0.64%
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test

Eli Lilly stock popped Wednesday after the company's weight-loss drug significantly reduced nighttime sleep apnea events.

Investor's Business Daily yesterday

LLY
-0.64%
RMD
Eli Lilly's weight loss drug could help sleep apnea patients

Shares of Eli Lilly (LLY) are slightly above their flatline Wednesday morning after the pharmaceutical giant announced positive results from a clinical trial of GLP-1 its weight loss drug Zepbound. The trial revealed that the drug helped patients with sleep apnea, a condition characterized by irregular breathing during sleep. The company is now moving to apply for an expanded label from the US Food and Drug Administration (FDA). If approved, it would allow Zepbound to be prescribed and used for the treatment of sleep apnea, in addition to its current weight loss use. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Angel Smith

Yahoo Finance Video yesterday

LLY
-0.64%
Eli Lilly's Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show

Wednesday, Eli Lilly And Co (NYSE:LLY) released topline results from SURMOUNT-OSA phase 3 trials of tirzepatide in obstructive sleep apnea (OSA), a sleep-related breathing disorder characterized by complete or partial collapses of the upper airway during sleep. The data showed that tirzepatide significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. Also Read: Eli Lilly Suffer

Benzinga yesterday

LLY
-0.64%
Eli Lilly’s Zepbound Weight Loss Drug Works on Sleep Apnea, Too

Lilly’s weight loss drug significantly reduced the severity of sleep apnea in obese adults in clinical trials.

Barrons.com yesterday

LLY
-0.64%
US STOCKS-Wall St gains from megacaps thrust; earnings, Fed comments on tap

Wall Street's main indexes rose on Wednesday, boosted by megacap growth stocks and as corporate results rolled in, while investors awaited commentary from Federal Reserve policymakers for clues on the economy's health. The benchmark S&P 500 and the Nasdaq closed lower in the previous session, impeded by climbing Treasury yields. Top U.S. central bank officials including Fed Chair Jerome Powell refrained from providing any guidance on when interest rates may be cut.

Reuters yesterday

COMP

^GSPC

^DJI
Eli Lilly Stock Gains After Study Shows Weight-Loss Drug Combats Sleep Apnea

A new study is boosting stock in drugmaker Eli Lilly—and knocking the shares of some medical-device makers. Eli Lilly’s drug Zepbound significantly reduced the severity of sleep apnea in patients in a new study, while also helping them lose weight. Obstructive sleep apnea is a disorder that blocks or restricts breathing during sleep, and obesity often contributes to it.

The Wall Street Journal yesterday

RMD

RSMDF

LLY
-0.64%

Performance Overview

Return	LLY	S&P 500
YTD	+28.19%	+5.06%
1-Year	+102.01%	+20.71%
3-Year	+308.62%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Company (LLY)

13 Best Low Volatility Stocks to Buy According to Hedge Funds

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025

India's Biocon developing its own version of Wegovy, clinical trial likely next year

Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?

Company News for Apr 18, 2024

Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

14 Best Large Cap Dividend Growth Stocks To Buy Now

2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years

The Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo

Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank

Top Research Reports for Eli Lilly, Linde & Caterpillar

Stocks Fall After Fed Data; Nvidia Tests Key Level While Tesla's Musk Faces Shareholder Vote

Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test

Eli Lilly's weight loss drug could help sleep apnea patients

Eli Lilly's Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show

Eli Lilly’s Zepbound Weight Loss Drug Works on Sleep Apnea, Too

US STOCKS-Wall St gains from megacaps thrust; earnings, Fed comments on tap

Eli Lilly Stock Gains After Study Shows Weight-Loss Drug Combats Sleep Apnea

Performance Overview